Related references
Note: Only part of the references are listed.Metformin and cancer therapy
Frederic Bost et al.
CURRENT OPINION IN ONCOLOGY (2012)
p53 Regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy
Zohar Attias-Geva et al.
EUROPEAN JOURNAL OF CANCER (2012)
Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway
Rabbie K. Hanna et al.
GYNECOLOGIC ONCOLOGY (2012)
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination
Christopher Korch et al.
GYNECOLOGIC ONCOLOGY (2012)
Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression
Lingling Dong et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2012)
Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer
H. Werner
ONCOGENE (2012)
Metformin Amplifies Chemotherapy-Induced AMPK Activation and Antitumoral Growth
Guilherme Z. Rocha et al.
CLINICAL CANCER RESEARCH (2011)
Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells
Zohar Attias-Geva et al.
EUROPEAN JOURNAL OF CANCER (2011)
Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells
Ya Xie et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2011)
The Mechanism of Action of the Histone Deacetylase Inhibitor Vorinostat Involves Interaction with the Insulin-Like Growth Factor Signaling Pathway
Rive Sarfstein et al.
PLOS ONE (2011)
The insulin-like growth factor-I receptor as an oncogene
Haim Werner et al.
ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY (2011)
Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4
Jun Song et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
AMPK-mediated GSK3β inhibition by isoliquiritigenin contributes to protecting mitochondria against iron-catalyzed oxidative stress
Song Hwa Choi et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells
Mahvash Zakikhani et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Health-Related Quality of Life and Mortality in a General and Elderly Population of Patients With Type 2 Diabetes (ZODIAC-18)
Gijs W. D. Landman et al.
DIABETES CARE (2010)
Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy
Leigh A. Cantrell et al.
GYNECOLOGIC ONCOLOGY (2010)
Identification of Insulin-Like Growth Factor-I Receptor (IGF-IR) Gene Promoter-Binding Proteins in Estrogen Receptor (ER)-Positive and ER-Depleted Breast Cancer Cells
Rive Sarfstein et al.
Cancers (2010)
Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro
Irina N. Alimova et al.
CELL CYCLE (2009)
New Users of Metformin Are at Low Risk of Incident Cancer A cohort study among people with type 2 diabetes
Gillian Libby et al.
DIABETES CARE (2009)
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
C. J. Currie et al.
DIABETOLOGIA (2009)
Targeting the IGF1 axis in cancer proliferation
Ilan Bruchim et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2009)
Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer
Sao Jiralerspong et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer
Marc J. Gunter et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
Targeting AMPK: A new therapeutic opportunity in breast cancer
Sirwan M. Hadad et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
Insulin and insulin-like growth factor signalling in neoplasia
Michael Pollak
NATURE REVIEWS CANCER (2008)
Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue
Theodore P. Ciaraldi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2006)
Transcriptional regulation of the insulin-like growth factor-1 receptor gene in breast cancer
Rive Sarfstein et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2006)
Association between adiponectin, insulin resistance, and endometrial cancer
Pamela T. Soliman et al.
CANCER (2006)
A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance
DY Xing et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
AD Santin et al.
BRITISH JOURNAL OF CANCER (2005)
PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells
H Zhao et al.
ONCOGENE (2004)
Geldanamycin treatment inhibits hemorrhage-induced increases in KLF6 and iNOS expression in unresuscitated mouse organs: role of inducible HSP70
JG Kiang et al.
JOURNAL OF APPLIED PHYSIOLOGY (2004)
In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model
P Frost et al.
BLOOD (2004)
Glycogen synthase kinase 3β is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase
SY Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Abnormalities in the NF-κB family and related proteins in endometrial carcinoma
J Pallares et al.
JOURNAL OF PATHOLOGY (2004)
Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells
X Jin et al.
BRITISH JOURNAL OF CANCER (2004)
Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model
L Uhrbom et al.
NATURE MEDICINE (2004)
GSK-3β inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression
E Beurel et al.
EXPERIMENTAL CELL RESEARCH (2004)
The TOR pathway: A target for cancer therapy
MA Bjornsti et al.
NATURE REVIEWS CANCER (2004)
PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatase activity of PTEN downregulates IGF-II expression in hepatoma cells
S Kang-Park et al.
FEBS LETTERS (2003)
Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control
S Oldham et al.
TRENDS IN CELL BIOLOGY (2003)
Dietary glycemic index, glycemic load and ovarian cancer risk: a case-control study in Italy
LSA Augustin et al.
ANNALS OF ONCOLOGY (2003)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
M Guba et al.
NATURE MEDICINE (2002)
Role of AMP-activated protein kinase in mechanism of metformin action
GC Zhou et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
M Hidalgo et al.
ONCOGENE (2000)